INMED PHARMACEUTICALS INC. Capital Expenditures
INMED PHARMACEUTICALS INC. (INM) reported Capital Expenditures of $0 for the 12-month period ending 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for the quarter ending 2024-03-31 was $2.00.
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for the quarter ending 2022-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for the quarter ending 2022-03-31 was $3.55K.
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for fiscal 2023 was $160.01K, a 309.16% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for fiscal 2022 was $39.11K, a 2167.13% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for fiscal 2021 was $1.73K, a 95.95% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. payments to acquire property, plant, and equipment for fiscal 2020 was $42.57K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 S-4 · filed 2026-07-02 | |||
| 2024-06-30 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $2.00 derived: sum of 2 quarters · filed 2026-07-02 | $9.29K S-4 · filed 2026-07-02 | |
| 2024-03-31 | $2.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $9.29K 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | $9.29K 10-Q · filed 2025-02-12 | |||
| 2023-06-30 | $160.01K 10-K · filed 2024-09-30 | |||
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $3.55K derived: sum of 2 quarters · filed 2023-09-29 | -$210.89K derived: sum of 3 quarters · filed 2023-09-29 | $39.11K 10-K · filed 2023-09-29 |
| 2022-03-31 | $3.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$210.89K derived: sum of 2 quarters · filed 2023-05-15 | $39.11K 10-Q · filed 2023-05-15 | |
| 2021-12-31 | -$214.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $35.55K 10-Q · filed 2023-02-17 | ||
| 2021-09-30 | $250.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $1.73K 10-K · filed 2022-09-23 | |||
| 2020-06-30 | -$923.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $7.87K derived: sum of 2 quarters · filed 2021-09-24 | $10.04K derived: sum of 3 quarters · filed 2021-09-24 | $42.57K 10-K · filed 2021-09-24 |
| 2020-03-31 | $8.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | $10.97K derived: sum of 2 quarters · filed 2021-05-13 | $43.50K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $2.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $34.70K 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | $32.53K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |